Keller Grover

Protecting Employees and Consumers

415-543-1305

  • Our Team
  • Practice Areas
    • Whistleblower Actions
    • Employment Violations
    • Antitrust Litigation
    • Consumer Protection
    • Title IX
  • FAQs
    • Whistleblower FAQs
    • Employment Law FAQs
    • Antitrust FAQs
    • Consumer Protection FAQs
  • News
  • Contact Us

Clinical Trial Fraud: When Research Misconduct Leads to False Claims Act Liability

Nov 02 2026

Free and Confidential
Case Review 24/7

415-543-1305

Se Habla Español

Keller Grover / News / Whistleblower News / False Claims Act / Clinical Trial Fraud: When Research Misconduct Leads to False Claims Act Liability

On December 16, 2025, Dana-Farber Cancer Institute agreed to pay $15 million to settle allegations that it made false statements and certifications in connection with National Institutes of Health (NIH) research grants. The conduct at issue spanned ten years, from 2014 to 2024. The case was brought by a whistleblower who did not work for Dana-Farber, and it shows that the False Claims Act reaches well beyond hospital billing. When taxpayer-funded research is built on falsified data, the institution that accepted the money can be held liable.

Dana-Farber Was Accused of Using Grant Funds on Research with Falsified Data

As part of the settlement, Dana-Farber admitted that its researchers used money from six NIH grants to conduct work that resulted in 14 published journal articles containing misrepresented or duplicated images and data. In some instances, the same image was reused to represent different experimental conditions. In others, images were rotated, magnified, or stretched so they appeared to show different results. The institute also admitted that a supervising researcher failed to provide adequate oversight and that it spent grant funds on costs that were not allowed.

The government also contended that a different researcher obtained four NIH grants after submitting applications that discussed a published article without disclosing that some of the images and data in that article had been misrepresented. Dana-Farber received credit for cooperating with the investigation, which may have been a factor in the final settlement amount.

The whistleblower in the case was a scientist who identified problems in Dana-Farber’s published research before filing a qui tam lawsuit in April 2024. The government later intervened to resolve the case.

How Research Misconduct Becomes a False Claim

Institutions that accept federal research grants agree to follow the terms and conditions of those awards. Each grant application, progress report, and request for funds includes a representation that the institution is conducting the research honestly and spending the money as the grant allows. When an institution obtains a grant based on fabricated results or keeps drawing down funds while it knows the underlying research is compromised, those representations are false.

The government relies on these submissions when it decides which research to fund. If the information it relied on was false, the institution may be liable under the False Claims Act, which allows the government to recover up to three times its losses, along with civil penalties for each false claim.

Dana-Farber is not an isolated case. In 2019, Duke University paid $112.5 million to resolve allegations that it submitted grant applications and progress reports to NIH and the Environmental Protection Agency that contained falsified research. In January 2025, Athira Pharma agreed to pay over $4 million to resolve allegations that it failed to report allegations of research misconduct to NIH in its grant applications and progress reports. The Athira case shows that an institution does not have to fabricate data itself to face liability. Concealing known problems can be enough.

Clinical Trials Create Additional Billing Risks

Clinical trials that involve human subjects have their own False Claims Act risk. Medicare covers certain routine costs for patients enrolled in qualifying clinical trials, but it does not pay for items and services that the trial sponsor provides for free or that are performed only to collect research data. When a hospital or research site bills Medicare for a test or procedure that the sponsor has already paid for, it is billing twice for the same service.

Research sites can also face scrutiny for fabricating trial data. Federal prosecutors have charged clinic operators with enrolling patients who did not meet eligibility criteria, falsifying lab results and medical records, and reporting that patients were taking a study drug when they were not. When falsified trial data supports a federally funded study, or when services connected to the trial are billed to Medicare or Medicaid, the False Claims Act may apply.

Who Generally Reports Research and Clinical Trial Fraud

Research misconduct is rarely visible to anyone outside the lab or the research site. Those who may have knowledge of it include:

  • Postdoctoral researchers, graduate students, and lab technicians who see data being altered or images being reused across experiments;
  • Clinical research coordinators who see patients enrolled despite failing eligibility criteria, or who are asked to change records after the fact;
  • Grant administrators and research billing staff who notice that sponsor-paid services are also being billed to Medicare; and
  • Research integrity and compliance staff whose concerns have been ignored by leadership.

The Dana-Farber case also shows that a whistleblower does not always have to be an insider or employee. In that case, an outside scientist with knowledge of the misconduct brought the lawsuit.

Speak to a Whistleblower Attorney About Research Fraud

If you have seen falsified data, concealed misconduct, or improper billing tied to federally funded research or a clinical trial, you can come forward. If the government recovers money, you may be entitled to a portion of what it receives as compensation for reporting the misconduct, and federal law protects you from retaliation by your employer. A whistleblower attorney at Keller Grover can review what you know, evaluate your case, and protect your rights throughout the process. Contact our legal team at Keller Grover today to discuss what you have seen.

 

  • Facebook
  • LinkedIn
  • YouTube

KELLERGROVER, LLP · 1965 Market St. San Francisco, CA 94103 · 415-543-1305 · info@kellergrover.com
© 2026 KELLERGROVER, LLP. All rights reserved · Disclaimer & Privacy Policy